ATAD2 and ovarian carcinoma: Collectively, these results identify ATAD2 as a novel driver of ovarian cancer cell growth and metastasis that functions via CENPE to prevent cell cycle arrest and apoptosis and suggest that ATAD2 can be targeted either alone or in combination with CENPE inhibitor to provide therapeutic benefits to ovarian cancer patients.